Cost Advantages of Combination Asthma Therapy
- 1 January 2004
- journal article
- Published by Springer Nature in Treatments in Respiratory Medicine
- Vol. 3 (3) , 133-137
- https://doi.org/10.2165/00151829-200403030-00001
Abstract
The addition of long-acting β2-adrenoceptor agonist (LABA) therapy to ‘low dose’ inhaled corticosteroids improves asthma outcomes in terms of lung function, exacerbation rates, and quality of life...Keywords
This publication has 20 references indexed in Scilit:
- Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroidsEuropean Respiratory Journal, 2002
- Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthmaRespiratory Medicine, 2000
- Cost Estimates for Chronic DiseasesDisease Management and Health Outcomes, 2000
- Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- A National Estimate of the Economic Costs of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.American Journal of Respiratory and Critical Care Medicine, 1996
- The costs of asthmaEuropean Respiratory Journal, 1996
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- An Economic Evaluation of Asthma in the United StatesNew England Journal of Medicine, 1992